PetIQ Inc (PETQ)
30.75
+0.01
(+0.03%)
USD |
NASDAQ |
Sep 27, 16:00
30.76
+0.01
(+0.03%)
After-Hours: 20:00
PetIQ SG&A Expense (TTM): 208.04M for June 30, 2024
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
Date | Value |
---|---|
June 30, 2024 | 208.04M |
March 31, 2024 | 203.12M |
December 31, 2023 | 196.24M |
September 30, 2023 | 191.25M |
June 30, 2023 | 182.22M |
March 31, 2023 | 177.65M |
December 31, 2022 | 182.56M |
September 30, 2022 | 186.27M |
June 30, 2022 | 185.54M |
March 31, 2022 | 178.08M |
December 31, 2021 | 170.52M |
September 30, 2021 | 161.70M |
June 30, 2021 | 152.01M |
March 31, 2021 | 147.36M |
December 31, 2020 | 138.38M |
September 30, 2020 | 134.61M |
Date | Value |
---|---|
June 30, 2020 | 128.39M |
March 31, 2020 | 114.35M |
December 31, 2019 | 103.20M |
September 30, 2019 | 93.06M |
June 30, 2019 | 81.34M |
March 31, 2019 | 73.83M |
December 31, 2018 | 72.26M |
September 30, 2018 | 64.02M |
June 30, 2018 | 57.13M |
March 31, 2018 | 49.47M |
December 31, 2017 | 37.90M |
September 30, 2017 | 34.96M |
June 30, 2017 | 32.16M |
March 31, 2017 | 31.19M |
December 31, 2016 | 31.84M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (TTM) Range, Past 5 Years
93.06M
Minimum
Sep 2019
208.04M
Maximum
Jun 2024
161.73M
Average
174.09M
Median
SG&A Expense (TTM) Benchmarks
Omeros Corp | 53.37M |
BioCardia Inc | 3.965M |
Revance Therapeutics Inc | 286.28M |
Zevra Therapeutics Inc | 43.01M |
Alector Inc | 57.09M |